Epimerase-Deficiency Galactosemia Is Not a Binary Condition  by Openo, Kimberly K. et al.
www.ajhg.org Openo et al.: Epimerase-Deﬁciency Galactosemia 89
Epimerase-Deﬁciency Galactosemia Is Not a Binary Condition
Kimberly K. Openo,1 Jenny M. Schulz,2,* Claudia A. Vargas,1,† Corey S. Orton,3
Michael P. Epstein,1 Rhonda E. Schnur,4 Fernando Scaglia,5 Gerard T. Berry,6
Gary S. Gottesman,8 Can Ficicioglu,7 Alfred E. Slonim,9 Richard J. Schroer,10 Chunli Yu,1
Vanessa E. Rangel,1 Jennifer Keenan,4 Kerri Lamance,5 and Judith L. Fridovich-Keil1
1Department of Human Genetics, Emory University School of Medicine, 2Graduate Program in Nutrition Health Sciences, Emory University,
and 3Emory College, Atlanta; 4Division of Genetics, Department of Pediatrics, Cooper University Hospital/Robert Wood Johnson Medical
School, Camden, NJ; 5Department of Molecular and Human Genetics, Texas Children’s Hospital and Baylor College of Medicine, Houston;
6Jefferson Medical College and 7Division of Metabolism, Children’s Hospital of Philadelphia, Philadelphia; 8SSM Cardinal Glennon Children’s
Hospital, St. Louis, MO; 9Columbia University Medical School, New York; and 10Greenwood Genetics Center, Greenwood, SC
Epimerase-deﬁciency galactosemia results from the impairment of UDP-galactose 4′-epimerase (GALE), the third
enzyme in the Leloir pathway of galactose metabolism. Originally identiﬁed as a clinically benign “peripheral”
condition with enzyme impairment restricted to circulating blood cells, GALE deﬁciency was later demonstrated
also to exist in a rare but clinically severe “generalized” form, with enzyme impairment affecting a range of tissues.
Isolated cases of clinically and/or biochemically intermediate cases of epimerase deﬁciency have also been reported.
We report here studies of 10 patients who, in the neonatal period, received the diagnosis of hemolysate epimerase
deﬁciency. We have characterized these patients with regard to three parameters: (1) GALE activity in transformed
lymphoblasts, representing a “nonperipheral” tissue, (2) metabolic sensitivity of those lymphoblasts to galactose
challenge in culture, and (3) evidence of normal versus abnormal galactose metabolism in the patients themselves.
Our results demonstrate two important points. First, whereas some of the patients studied exhibited near-normal
levels of GALE activity in lymphoblasts, consistent with a diagnosis of peripheral epimerase deﬁciency, many did
not. We detected a spectrum of GALE activity levels ranging from 15%–64% of control levels, demonstrating that
epimerase deﬁciency is not a binary condition; it is a continuum disorder. Second, lymphoblasts demonstrating the
most severe reduction in GALE activity also demonstrated abnormal metabolite levels in the presence of external
galactose and, in some cases, also in the absence of galactose. These abnormalities included elevated galactose-1P,
elevated UDP-galactose, and deﬁcient UDP-glucose. Moreover, some of the patients themselves also demonstrated
metabolic abnormalities, both on and off galactose-restricted diet. Long-term follow-up studies of these and other
patients will be required to elucidate the clinical signiﬁcance of these biochemical abnormalities and the potential
impact of dietary intervention on outcome.
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In both prokaryotes and eukaryotes, galactose is me-
tabolized predominantly via the Leloir pathway, a series
of reactions catalyzed by the enzymes galactokinase
(GALK [EC 2.7.1.6]), galactose-1-phosphate uridylyl-
transferase (GALT [EC 2.7.7.12]), and UDP-galactose
4′-epimerase (GALE [EC 5.1.3.2]) (ﬁg. 1) (Holton et al.
2000). Impairment of any of these three enzymes in hu-
mans results in galactosemia, although the symptoms
and severity depend on the identity of the enzyme im-
paired and the extent of the deﬁciency, among other
factors.
The ﬁrst clinically recognized form of galactosemia
was profound transferase deﬁciency (MIM 230400), re-
ported by Goppert (1917). This so-called classic galac-
tosemia occurs with a frequency of 1/30,000 to 1/60,000
live births in the United States and in other multiethnic
populations, and it is panethnic. If untreated, classic ga-
lactosemia can lead to rapid neonatal demise. Symptoms
progress from vomiting and diarrhea to cataracts and
failure to thrive to hepatomegaly, liver dysfunction with
bleeding diathesis, and Escherichia coli sepsis, culmi-
nating in neonatal death (Holton et al. 2000). Classic
galactosemia is often detected presymptomatically in
most industrialized nations by newborn screening and
is treated by lifelong dietary restriction of galactose. Al-
though this intervention resolves the acute and poten-
tially lethal symptoms of classic galactosemia, unfortu-
nately, a spectrum of complications persist, including
ataxia, learning disabilities, and verbal dyspraxia in
130% of patients and primary ovarian failure in 180%
of females (Waggoner et al. 1990). The pathophysiology
of classic galactosemia remains unclear, hindering the
development of more-effective therapies.
The second form of galactosemia to be recognized
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Figure 1 Reactions catalyzed by human enzymes of the Leloir
pathway of galactose metabolism
clinically was GALK deﬁciency (MIM 230200), ﬁrst re-
ported by Gitzelmann (1967). Patients with GALK de-
ﬁciency demonstrate none of the potentially lethal de-
velopmental, cognitive, or ovarian complications seen in
classic galactosemia but do present with neonatal cat-
aracts, which generally self-resolve upon dietary restric-
tion of galactose. On the basis of biochemical ascer-
tainment of carriers in a select white population, GALK
deﬁciency was estimated to affect 1/40,000 to 1/50,000
newborn infants (Mayes and Guthrie 1968). One large
population study, however, indicated that the frequency
of detectable GALK deﬁciency at birth is signiﬁcantly
!1/100,000 (Levy 1980).
The third and most poorly understood form of ga-
lactosemia is epimerase deﬁciency (MIM 230350). First
hypothesized by Kalckar (1965) and ﬁrst reported by
Gitzelmann (1972), epimerase-deﬁciency galactose-
mia was originally described as a benign condition in
which human GALE (hGALE) impairment was re-
stricted to the circulating red blood cells (RBC) and
white blood cells (Gitzelmann 1972; Gitzelmann and
Steimann 1973). Fibroblasts, liver, phytohemagglutinin
(PHA)-stimulated leukocytes, and Epstein Barr virus
(EBV)–transformed lymphoblasts from these patients all
demonstrated normal or near-normal levels of hGALE
activity (Gitzelmann 1972; Gitzelmann and Steimann
1973; Mitchell et al. 1975; Gitzelmann et al. 1977),
which lead to the designation of this condition as “pe-
ripheral” epimerase deﬁciency (Holton et al. 2000).
Soon thereafter, however, a second form of epimerase-
deﬁciency galactosemia became apparent when Holton
and colleagues (1981) reported a patient who, despite
normal GALT activity, presented with symptoms remi-
niscent of classic galactosemia and demonstrated se-
verely impaired GALE activity in both RBCs and ﬁbro-
blasts. This patient, whose acute clinical symptoms res-
ponded to dietary restriction of galactose, was said to
have “generalized” epimerase deﬁciency. Subsequent
studies revealed four additional patients with generalized
epimerase-deﬁciency galactosemia, ostensibly derived
from two different families (Sardharwalla et al. 1988;
Walter et al. 1999), although all ﬁve patients later proved
to be homozygotes for the same mutation, V94M (Wal-
ter et al. 1999; Wohlers et al. 1999), raising the sus-
picion that they might share common ancestry. Together,
these reports supported the conclusion that epimerase-
deﬁciency galactosemia was a binary condition, with a
benign peripheral form occurring at a population fre-
quency of 1/6,700 to !1/60,000, depending on the racial
group (Alano et al. 1998), and a severe generalized form
occurring at an extremely low frequency (Holton et al.
2000).
The conclusion that hGALE deﬁciency is a binary con-
dition held until the 1990s, when groups in both Europe
and the United States reported individual patients with
partial or tissue-speciﬁc GALE impairment and who ex-
hibited isolated clinical abnormalities. For example, Shin
and colleagues (Endres and Shin 1990; Schulpis et al.
1993; Shin et al. 2000) described patients with GALE
impairment in the lens who presented with cataracts,
and both Quimby et al. [1997] and Alano et al. [1998]
described a patient with partial GALE deﬁciency who
was clinically well as an infant but who gradually man-
ifested notable developmental/cognitive delay, starting
after his ﬁrst year of life. This patient exhibited only
∼15% of normal levels of GALE activity in his trans-
formed lymphoblasts (Quimby et al. 1997). It is impor-
tant to point out that, although lymphoblasts are clearly
derived from peripheral cells, with regard to GALE ac-
tivity they more closely resemble nonperipheral cells
(Mitchell et al. 1975) and, as such, offer a convenient
tool for distinguishing peripheral from nonperipheral
forms of epimerase-deﬁciency galactosemia. While these
cases clearly raised concern that epimerase deﬁciency
might not be a binary condition, the broader clinical
signiﬁcance of these isolated ﬁndings remained unclear.
We report here the biochemical and genetic studies of
a cohort of 10 additional and unrelated epimerase-de-
ﬁcient patients accrued over a 4-year period and char-
acterized, relative to controls, with regard to epimerase
activity in transformed lymphoblasts as well as met-
abolic sensitivity of those lymphoblasts to galactose
exposure in culture. Using these samples, we asked two
fundamental questions: (1) Do all infants/children who
receive the diagnosis of hemolysate epimerase deﬁciency
exhibit normal GALE activity in their nonperipheral tis-
sues, as represented by transformed lymphoblasts, and
(2) is there any abnormal metabolic consequence to par-
tial impairment of hGALE activity in patients or patient
lymphoblasts exposed to environmental galactose?
The answer to the ﬁrst question was “no.” Our data
clearly demonstrated that, at least in biochemical terms,
epimerase deﬁciency is not binary; it is a continuum
disorder. We observed GALE activity levels in lympho-
blasts from patients that ranged from a low of ∼15%
of control levels to a high of 64% of control levels.
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The answer to the second question was “yes.” Our
results demonstrated that lymphoblasts with as much as
35% residual GALE activity nonetheless exhibited met-
abolic abnormalities upon exposure to environmental
galactose. Furthermore, some of the patients fromwhom
those lymphoblasts were derived also demonstrated
abnormal galactose metabolites. The relationship be-
tween these metabolic abnormalities and the possibility
of clinical abnormalities later in life remains unclear.
Long-term clinical follow-up studies of signiﬁcantly
larger numbers of patients with partial GALE deﬁ-
ciency will be required to address this question.
Material and Methods
Study Subjects
All patients were ascertained by referral, and we obtained
their consent in accordance with Emory University Institu-
tional Review Board Protocol 618–99 (primary investigator:
Fridovich-Keil). Controls were ascertained as anonymous
blood samples from nongalactosemic individuals. All hemo-
lysate biochemical data were generated in clinical labs, as
noted, and all clinical follow-up data were reported by refer-
ring health care professionals.
Lymphoblast Culture
EBV-transformed lymphoblasts were prepared and cultured
from patient or control blood samples as described elsewhere
(Neitzel 1986), with a substitution of interleukin-2 in place of
cyclosporine. Transformed lymphoblasts were maintained in
RPMI 1640 medium containing 11.1 mM glucose (2 g/liter)
and 0.3 g/liter L-glutamine and were supplemented with pen-
icillin (100 U/ml), streptomycin (100 mg/ml), 25 mM HEPES
(Cellgro), and 10% (v/v) fetal bovine serum (Gibco). All cells
were maintained at 37C in a humidiﬁed 5% CO2 incubator
(NuAire).
GALT and GALE Enzyme Analyses
Soluble protein lysates were prepared from 0.15 g trans-
formed lymphoblast cell pellets as follows. Cells were har-
vested by centrifugation, were washed with 1# PBS to remove
residual medium, and were resuspended in 300 ml of 100-mM
glycine buffer (pH 8.7) containing protease inhibitor cocktail
(Roche). Cells were disrupted on ice by three 15-s exposures
to a Misonix Sonicator 3000 with microtip at output level 1.0.
Insoluble debris was removed from each sample by centrifu-
gation in an Eppendorf 5415D at 13.2 rpm at 4C, and the
supernatant was passed over a P-30 Bio-Spin Column (Bio-
Rad) to remove small molecules before further analysis. Protein
concentrations were determined using the Bio-Rad protein as-
say reagent with BSA as the standard, as recommended by the
manufacturer.
Both GALT and GALE activities were measured in samples
of each cell lysate by use of enzymatic assay procedures, es-
sentially as described elsewhere (Ross et al. 2004; Schulz et al.
2005), with separation and quantiﬁcation of reactants and
products achieved by high-performance liquid chromatogra-
phy (HPLC). GALE assays were performed at 37C with the
use of both UDP-galactose (UDP-Gal) and UDP-N-acetylga-
lactosamine (UDP-GalNAc) substrates, with a 30-min incu-
bation time and 7.5–30 mg total protein in a ﬁnal volume of
12.5 ml. UDP-Gal GALE activity assays contained 40 mM gly-
cine, 0.4 mM UDP-Gal, and 8 mM NAD. UDP-GalNAc
GALE activity assays contained 40 mM glycine, 0.4 mMUDP-
GalNAc, and 8 mM NAD. GALT assays were performed at
37C for 60 min with the use of 50–100 mg total protein in
125 mM glycylglycine (pH 7.5) and 4.1 mM UDP-glucose
(UDP-Glc) in a ﬁnal volume of 50 ml. GALT activity assays
for each sample were performed in both the presence and ab-
sence of 1 mM galactose 1-phosphate (Gal-1P) to reveal back-
ground production of UDP-Gal (from UDP-Glc) by epimerase.
To determine GALT activity, formation of UDP-Gal in the
absence of Gal-1P was subtracted from the amount of UDP-
Gal produced in the presence of Gal-1P. All reactions were
initiated by the addition of protein and were monitored to
ensure linearity. GALE and GALT reactions were stopped by
the addition of 237.5 ml or 450 ml, respectively, of chilled sterile
water and were then ﬁltered (0.2-mm nylon ﬁlters [Alltech])
and subjected to HPLC separation and quantiﬁcation of sub-
strates and products. Enzyme activity was deﬁned by picomole
of product formed per microgram of protein per minute, under
the conditions described. HPLC separation and quantiﬁcation
of enzymatic substrates and products was achieved as de-
scribed elsewhere (Ross et al. 2004; Schulz et al. 2005).
Analysis of Metabolites from Lymphoblasts Cultured in the
Presence versus the Absence of Environmental Galactose
Cells were cultured in the absence of galactose, as described
above, until time zero, at which point ( ) the samples weretp 0
harvested for both external and internal metabolites, and ga-
lactose was added to the remainder of the culture for a ﬁnal
concentration of 0.5 mM. Cultures were harvested 24 h after
galactose addition. At each time point, 50 ml of cell suspension
was removed for protein determination by use of the BioRad
DC system, as recommended by the manufacturer. To monitor
external galactose, 250 ml of culture medium was added di-
rectly into 500 ml 60% MeOH at 20C, was mixed, and was
centrifuged brieﬂy at 13,200 rpm at 4C in an Eppendorf
5415C microcentrifuge to remove cellular debris. Then, 375
ml of supernatant was dried under vacuum without heat, was
rehydrated in 390 ml sterile Milli-Q water, and was ﬁltered
before HPLC fractionation. Internal metabolites were ex-
tracted from 10-ml samples of cell suspension harvested by
centrifugation at 3,500 rpm in Sorvall RT6000B at room tem-
perature and were washed once with PBS before further ma-
nipulation. Samples were prepared using a modiﬁed form of
the procedure described elsewhere by our laboratory (Ross et
al. 2004; Schulz et al. 2005) and originally described by Smits
et. al (1998).
In brief, each washed cell pellet was resuspended in 1.1 ml
cold PBS, of which 100 ml were used for protein determination
via the Bio-Rad DC protein assay, as recommended by the
manufacturer. Cells from the remaining 1 ml of suspension
were collected by high-speed centrifugation at 4C in an Ep-
pendorf 5415Cmicrocentrifuge. Intracellular metaboliteswere
extracted by vigorous agitation of the cells for 45 min at 4C
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Table 1
PCR Primers Used
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 2
PCR Programs Used to Amplify Segments of the
hGALE Gene
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
in a ﬁnal volume of an 875-ml 4:2:1 mixture of CHCl3/MeOH/
water. The aqueous layer was collected after repeated high-
speed centrifugation for 10 min at 4C. The remaining organic
phase was back-extracted a second time with 125 ml MeOH
and 125 ml water. Aqueous layers were combined and dried
under vacuum without heat (for ∼6 h). Each dried metabolite
pellet was rehydrated with a volume of sterile Milli-Q water
calculated from the protein level measured for that cell sus-
pension, with the use of 1 ml of water for every 5 mg of protein
detected. Rehydrated samples were ﬁltered through 0.2-mm
nylon ﬁlters (Alltech) before being loaded into the HPLC
autosampler.
HPLC analysis was performed using a DX600 or ISC2500
HPLC system (Dionex), each consisting of a Dionex AS50
autosampler, a Dionex GP50 gradient pump, and a Dionex
ED50 electrochemical detector. As described elsewhere, car-
bohydrates were separated on a CarboPac PA10 column (250
# 4 mm) with an amino-trap (50 # 14 mm) placed before
the analysis column and a borate-trap (50 # 4 mm) placed
before the injector port to remove trace amounts of borate
from the mobile phase buffers (Ross et al. 2004; Schulz et al.
2005). For all samples, 20 ml were injected into a 25-ml injec-
tion loop. Samples were maintained at 4C in the autosampler
tray, and the chromatography was performed at room
temperature.
Mobile phase buffers for the separation of carbohydrates
were used as described above. Flow rate was maintained at
0.8–1.0 ml/min. To prevent carbonate contamination of the
analysis column, a 50% sodium hydroxide solution containing
!0.04% sodium carbonate was used to prepare mobile phase
buffers (Fisher). Buffers were degassed and maintained under
a helium atmosphere.
All carbohydrate metabolites were separated as described
elsewhere (Ross et al. 2004; Schulz et al. 2005). In brief, hex-
oses and hexose-phosphates were separated using buffers A
(15 mM NaOH) and B (50 mM NaOH/1 M NaAC) mixed
using a low-salt gradient procedure with ﬂow rate of 1 ml/
min. The sample injection occurred at . Gradient 1: 98%tp 0
A and 2% B (10 to 8 min), a linear increase of B to 30%
(8–15 min), a linear increase of B to 50% (15–25 min), hold
50% A and 50% B (25–30 min), and a linear decrease of B
to 2% (30–35 min). External galactose was determined using
a low-salt gradient procedure with a ﬂow rate of 1 ml/min.
Gradient 2: 98% B and 2% B (5 to 5 min), a linear increase
of B to 50% (5–10 min), hold 50% A and 50% B (10–15
min), and a linear decrease of B to 2% (15–17 min). UDP-
hexoses were separated using a high-salt gradient procedure
with a ﬂow rate of 0.8 ml/min. Gradient 3: 50% A and 50%
B for (5 to 1 min), a linear increase of B to 70% (1–22 min),
hold 30% A and 70% B (22–27 min), and a linear decrease
of B to 50%. Carbohydrates were detected and were quantiﬁed
as described elsewhere (Ross et al. 2004; Schulz et al. 2005).
Mutational Analysis of the hGALE Locus
Genomic DNA was isolated from lymphoblast cells, as de-
scribed elsewhere, by use of phenol/chloroform extraction (Da-
vis et al. 1994). The GALE locus, including all introns and
segments stretching from 430 bp upstream of the start codon
to 491 bp downstream of the stop codon, were PCR ampliﬁed
in seven overlapping fragments by use of anMJ Research PTC-
150 minicycler with Eppendorf TripleMaster enzyme (Brink-
mann), in accordance with the manufacturer’s recommenda-
tions. PCR primer sequences are presented in table 1. All PCR
programs included a 5-min initial denaturation (at 94C) fol-
lowed by 32 cycles of denaturation, annealing, and extension.
The annealing temperatures and extension times used to am-
plify each fragment varied according to primer melting tem-
perature and anticipated product size (see table 2). After am-
pliﬁcation, PCR products were veriﬁed on 1% agarose gels
and were puriﬁed using the PureLink PCR Puriﬁcation Kit
(Invitrogen), in accordance with the manufacturer’s instruc-
tions. Sequencing reactions were performed by Macrogen.
Statistical Methods
We conducted tests of normality for enzyme activity levels
separately in cases and controls, using a Shapiro-Wilk (Shapiro
and Wilk 1965) test, as implemented in SAS PROC UNIVAR-
IATE. We also estimated and tested the correlation between
the activity levels of different enzymes separately in cases and
controls, using a Spearman correlation coefﬁcient (Hotelling
and Pabst 1936), as implemented in SAS PROC CORR. Fi-
nally, for a particular enzyme, we examined whether the ac-
tivity levels differed across different groups, using either a
Kolmogorov-Smirnov test (Kolmogorov 1941) (assuming two
groups) or a Kruskal-Wallis test (Kruskal 1952) (assuming
more than two groups), as implemented in SAS PROC
NPAR1WAY. For the Kolmogorov-Smirnov and Kruskal-Wal-
lis tests, we determined exact P values to ensure valid inference
in the presence of a small sample size.
Results
Deﬁning the Normal Range of hGALE Activity in
Human Lymphoblasts
Before initiating studies of hGALE activity in lym-
phoblasts derived from patients with RBC hGALE im-
pairment, we ﬁrst sought to deﬁne the range of hGALE
activity in lymphoblasts derived from control subjects.
Toward this end, we established 10 control lines and
characterized each with regard to both hGALE and
hGALT activities. Because normal hGALE catalyzes
both the interconversion of UDP-Gal/UDP-Glc and the
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Figure 2 Enzyme activities in control lymphoblasts. Values plotted represent average speciﬁc activity  SEM ( ). Numbers listedN  3
above each bar are normalized to the mean of the set. C1–C10 designate the individual control cell lines studied. A, hGALE activity with regard
to UDP-Gal. B, hGALE activity with regard to UDP-GalNAc. C, hGALT activity.
interconversion of UDP-GalNAc/UDP-GlcNAc (Piller et
al. 1983; Schulz et al. 2004), we measured both reac-
tions. Our results, presented in ﬁgure 2, demonstrate
three important points.
First, while hGALE activity values with regard to any
one substrate (UDP-Gal or UDP-GalNAc) and any one
cell line were highly reproducible, even across separate
cell harvests, these values varied from line to line. For
example, GALE activity values with regard to UDP-Gal
differed by up to almost a factor of two in pairwise
comparisons between samples. The height of each bar
plotted in ﬁgure 2 represents the hGALE speciﬁc activity
for that sample; the number listed over each bar rep-
resents the same value normalized to the mean of the
entire set. Results from Shapiro-Wilk tests ( )Pp .0083
suggest that these values are not normally distributed,
although these tests are likely sensitive to the small sam-
ple size considered in the study. With the assumption
that these control lymphoblast lines biochemically reﬂect
the individuals fromwhom they were derived, as appears
to be the case for patient lymphoblasts characterized
elsewhere with regard to hGALE (Quimby et al. 1997),
this observation suggests that healthy subjects exhibit
levels of hGALE activity that vary by up to a factor of
two. In comparison, activities measured for a single cell
line harvested and assayed at different times varied by
no more than 15% (data not shown). The genetic, en-
vironmental, or other factors that underlie this individ-
ual-to-individual variation remain unclear.
The second important point illustrated in ﬁgure 2 is
that, whereas hGALE activity levels in different cell lines
varied for both substrates, they varied much less with
regard to UDP-GalNAc than with regard to UDP-Gal.
Furthermore, there was modest, albeit not statistically
signiﬁcant, evidence to suggest that the hGALE activities
toward the two substrates were correlated (Spearman
correlation 0.507; ).Pp .130
The third point illustrated in ﬁgure 2 is that, despite
variations in hGALE activity, the hGALT activities de-
tected in these same cell lines varied by !1.5-fold. Fur-
thermore, as expected, there was no evidence for positive
correlation between either the UDP-Gal or the UDP-
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Figure 3 Enzyme activities in patient hemolysates and lymphoblasts. FKE numbers designate the individual patients enrolled in this study.
A, RBC hGALE. Values plotted represent individual measurements of hemolysate hGALE speciﬁc activity with regard to UDP-Gal. Each asterisk
(*) represents a missing value. Shaded area represents the control range for the assay, as reported by the clinical laboratory performing the
assay. B, Lymphoblast hGALE. Values plotted represent average speciﬁc activity  SEM ( ) with regard to UDP-Gal. Numbers listedN  3
above each bar are normalized to the mean of the corresponding control set. Shaded area represents the range of corresponding control activities.
C, Lymphoblast hGALE. Values plotted represent average speciﬁc activity SEM ( ) with regard to UDP-GalNAc. Numbers listed aboveN  3
each bar are normalized to the mean of the corresponding control set. Shaded area represents the range of corresponding control activities. D,
Lymphoblast hGALT. Values plotted represent average speciﬁc activity  SEM ( ). Numbers listed above each bar are normalized to theN  3
mean of the corresponding control set. Shaded area represents the range of corresponding control activities. Ave p average; prot p protein.
GalNAc activities of hGALE and hGALT activity
(Spearman correlation 0.232 and 0.031, respec-
tively; and , respectively).Pp .520 Pp .920
A Spectrum of GALE Impairment in Patient
Lymphoblasts
To deﬁne the extent of hGALE impairment in non-
peripheral cells from infants with RBC hGALE impair-
ment, we repeated the study described above with the
use of lymphoblasts from 10 unrelated patients previ-
ously identiﬁed as RBC hGALE deﬁcient in a clinical
lab. Available RBC GALE data on these patients are
presented in ﬁgure 3A.
The deﬁnition of peripheral epimerase deﬁciency dic-
tates that, whereas hGALE activity is impaired in hem-
olysates, it is normal or near-normal in nonperipheral
cells, including ﬁbroblasts and transformed lympho-
blasts (Gitzelmann 1972; Mitchell et al. 1975). None-
theless, our results clearly demonstrated a spectrum of
lymphoblast hGALE activities in the cohort of patients
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Figure 4 Metabolites in control and patient lymphoblasts exposed to galactose. A, External galactose in the medium of control and
patient lymphoblasts at (open bar) and at h after addition of 0.5 mM galactose to the medium (shaded bar). Values plotted aretp 0 tp 24
average  SEM ( ). Control values were averaged from each of six different control cell lines (C1, C2, C3, C5, C7, and C10), eachN  3
assayed three times. Patient cell lines designated “low,” “medium,” and “high” hGALE had !20%, 30%–40%, and 150%, respectively, of
control (mean of the control set) hGALE activity with regard to UDP-Gal. B, Internal Gal-1P. Values plotted are average  SEM ( ) forNp 3
each cell line. Open bars represent ; shaded bars represent h after addition of 0.5 mM galactose to the medium. C, Internal UDP-tp 0 tp 24
Gal. Values plotted are average  SEM ( ) for each cell line. Open bars represent ; shaded bars represent h after additionNp 3 tp 0 tp 24
of 0.5 mM galactose to the medium. D, Internal UDP-Glc. Values plotted are average  SEM ( ) for each cell line. Open bars representNp 3
; shaded bars represent h after addition of 0.5 mM galactose to the medium.tp 0 tp 24
studied, ranging from a low of ∼15% of the control
mean to a high of ∼64% of the control mean (ﬁg. 3B).
The integrity of each lysate was conﬁrmed by analysis
of hGALT, which demonstrated consistently normal ac-
tivity (ﬁg. 3D). Whereas small sample size and nonran-
dom ascertainment prevent extension from these data to
estimate the population distribution of lymphoblast
hGALE in RBC hGALE–deﬁcient individuals as a group,
the conclusion that many of these patients have hGALE
impairment that extends to their lymphoblasts is un-
avoidable. Indeed, a Kolmogorov-Smirnov test of dif-
ference between controls and cases for UDP-Gal activity
produced an exact P value of . Unexpect-51.09# 10
edly, comparison of the hGALE deﬁciency in these pa-
tients with regard to both substrates demonstrated that
enzyme activities with regard to UDP-Gal and UDP-
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GalNAc were not signiﬁcantly correlated (correlation
0.030; . Indeed, the patient exhibiting thePp .9338
most severe impairment with regard to UDP-Gal
(FKE35, ∼15% of control) demonstrated essentially nor-
mal activity with regard to UDP-GalNAc (∼90% of con-
trol). Conversely, the patient exhibiting the most se-
vere impairment with regard to UDP-GalNAc (FKE52,
∼29% of control) exhibited one of the higher activities
with regard to UDP-Gal (∼53% of control).
Finally, data presented in ﬁgure 3A and 3B illustrate
that, whereas the RBC hGALE values reported for these
10 patients varied by 120-fold, they showed no signif-
icant evidence of correlation with the lymphoblast
hGALE activities detected (correlation 0.280; Pp
). There are many possible explanations for this lack.434
of correlation among the RBC hGALE activity values
determined in the clinical labs, ranging from differences
in the expression or function of different hGALE alleles
in different cell types to the potential impact of diet or
other biological factors or even to varying shipping and
handling conditions or differing assay conditions. In-
deed, the fact that repeat clinical assays on two of the
patients in this study varied internally by close to a factor
of 3 (FKE52 and FKE55) demonstrates the inherent var-
iability in these values.
Metabolic Consequence of Partial GALE Impairment in
Human Lymphoblasts
Whereas studies of GALE enzyme activity in vitro are
useful, the more important parameter to measure is the
metabolism of galactose in living cells. Toward that end,
we monitored the metabolic response of selected control
and patient lymphoblasts cultured in the presence and
absence of 0.5 mM galactose. In brief, cells cultured in
standard RPMI 1640 medium (containing 11.1 mM glu-
cose) were divided into duplicate ﬂasks at time zero, and
0.5 mM galactose was added to one ﬂask from each set.
External galactose and internal Gal-1P, UDP-Gal, and
UDP-Glc were then monitored in samples harvested at
0 h and 24 h from these cultures (ﬁg. 4). Twelve lines
were studied, including six control and six patient lines.
The control lines were selected to represent the spectrum
of hGALE values evident in the control population stud-
ied (C1, C2, C3, C5, C7, and C10). The patient lym-
phoblasts were selected to include the two “lowest
hGALE UDP-Gal activity” lines (FKE35 and FKE57),
two “intermediate hGALE activity” lines (FKE33 and
FKE56), and the two “highest hGALE activity” lines
(FKE50 and FKE55).
With regard to external metabolites, by 24 h, all the
control lines had consumed ∼50% of their galactose. In
contrast, the two patient lines with the lowest hGALE
activity had each consumed less than ∼15% of their
galactose. The patient lines with the intermediate and
highest level hGALE activity had each consumed be-
tween ∼19% and ∼50% of their galactose (ﬁg. 4A). A
Kruskal-Wallis test of difference between the four groups
monitored (control and patient low, medium, and high)
demonstrated that, whereas, as expected, there was no
signiﬁcant difference in the starting ( ) external ga-tp 0
lactose values for the four cultures (exact ),Pp .3817
by 24 h, the levels of galactose remaining for the different
groups of cells were signiﬁcantly different from one an-
other (exact ).Pp .0088
With regard to internal metabolites, many of the pa-
tient lines again displayed abnormalities. For example,
whereas all of the control cell lines accumulated 6–7
pmol Gal-1P/mg protein after exposure to galactose, the
most severely hGALE-impaired patient lines accumu-
lated nearly twice that amount (ﬁg. 4B). Similarly,
whereas galactose exposure had little effect on UDP-Gal
accumulation in control lymphoblasts, UDP-Gal levels
in the patient cells essentially doubled in the presence of
galactose for all but those with the highest hGALE ac-
tivity. It is interesting to note that even basal UDP-Gal
levels (in the absence of galactose exposure) were higher
in the more severely affected patient lines, perhaps re-
ﬂecting the altered metabolism of sugars scavenged from
serum glycoproteins and glycolipids. Finally, whereas
every control line demonstrated either unchanged or el-
evated UDP-Glc in response to galactose exposure, al-
most every patient line demonstrated depressed UDP-
Glc after exposure to galactose. A Kruskal-Wallis test of
difference between the four groups at 24 h was highly
signiﬁcant (exact ). Although the quantitativePp .0046
distinctions between control and patient lines for these
internal metabolites were not huge, given the limited
nature of the hGALE impairment, they were nonetheless
remarkable.
RBC Metabolic Consequences of Partial GALE
Impairment in Patients on Normal versus Galactose-
Restricted Diets
Our lymphoblast studies clearly suggested that partial
impairment of hGALE can result in metabolic abnor-
malities for cells exposed to galactose in culture. None-
theless, how well do these results mimic the metabolic
reality for patients? To address this question, we col-
lected as much dietary and metabolic information as
possible with regard to the patients enrolled in this study.
Although this information was unavailable for some pa-
tients, for others we were able to learn if and when
dietary restriction of galactose was initiated and/or dis-
continued and how RBC Gal-1P values responded to
these changes in diet. The results were striking. In brief,
whereas all the patients presumably exhibited elevated
RBC galactose plus Gal-1P levels as neonates on normal
diet—which is, in part, how they were ascertained by
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Table 3
Gal-1P Levels Detected in the Hemolysates of Patients
Patient
Birth
Year Sexa Raceb Gal-1P Valuesc Normal Range
FKE33 1999 M L .15*, .04*, 1.13, .05*, .09* mmg/g hgb 0–.17 mmg/g hgb
FKE34 2001 F H 4.5, 3.6*, .25*, .59*, .47 mg/100 ml RBCs !1 mg/100 ml RBCs
FKE35 2002 F MR .0*, .94*, 3.2*, .07*, .07*, .0, .0 mg/100 ml RBCs !1 mg/100 ml RBCs
FKE37 2001 F H .02*, .06*, .06*, .01*, 0.28*, .05*, .00*, .24, .24, .52, .24, .34 mmg/g hgb 0–.17 mmg/g hgb
FKE50 2003 F AA 31.8, .00*, .06 mg/100 ml RBCs !1 mg/100 ml RBCs
FKE51 2003 M AA Unknown …
FKE52 2003 F AA 2.1, .7*, .26* mg/100 ml RBCs !1 mg/100 ml RBCs
FKE55 2004 UK AS 11.2, !1 mg/100 ml RBCs (diet unknown) !1 mg/100 ml RBCs
FKE56 2004 M AA .0 (diet unknown), !1* mg/100 ml RBCs !1 mg/100 ml RBCs
FKE57 2004 M AA !.1* mg/100 ml RBCs !1 mg/100 ml RBCs
a UK p sex unknown.
b L p Latin American, H p Hispanic, MR p mixed race, AA p African American, and AS p Asian.
c Gal-1P values are listed chronologically in terms of the order in which the test was performed. Values listed in bold italics are
abnormal. An asterisk indicates that the patient was on a galactose-restricted diet at the time of testing. Values without an asterisk
indicate that the patient was on a normal diet at the time of testing.
the newborn screening programs—these Gal-1P values
all essentially normalized in response to dietary restric-
tion of galactose. Many of these children were later chal-
lenged with dietary galactose or were removed from di-
etary restriction altogether, and, whereas some dem-
onstrated normal RBC Gal-1P values on relaxed diets
later in childhood, others did not (table 3). Of note, one
patient in this study (FKE37) demonstrated ﬁve consec-
utive abnormal RBC Gal-1P values following discontin-
uation of dietary galactose restriction. Another patient
with marked lymphoblast hGALE impairment (FKE35)
demonstrated inconsistent Gal-1P levels on dietary re-
striction but later demonstrated normal Gal-1P values
despite a diet that contained galactose. This same patient
also demonstrated abnormally low levels of RBC gal-
actitol and galactonate while on dietary restriction (e.g.,
0.16 mmol/liter [normalSDp 1.25 0.35 mmol/liter]
and 0.18 mmol/liter [normalSDp 3.72 1.16 mmol/
liter], respectively) (Ficicioglu et al. 2005); these values
rose slowly back toward the normal range (0.62 mmol/
liter and 2.26 mmol/liter, respectively) when galactose
was restored to her diet.
A Study of GALE Heterozygotes
In addition to studying hGALE-impaired patients, we
also explored the possibility of enzyme or metabolic im-
pairment in the lymphoblasts of obligate hGALE het-
erozygotes—namely, the parents of one of the most se-
verely affected patients in our group (FKE35). As
predicted, the hGALE enzyme activities detected in these
lines (65% of control and 70% of control) were inter-
mediate between the mean value for controls and the
level seen in their child, which placed them at the low
end of the normal range. The RBC GALE activity level
in one parent was 13.1 mmol UDP-Glc/h/g hemoglobin
(hgb), which is within the reported carrier range (12.0–
20.0 mmol UDP-Glc/h/g hgb) (Shin 1991), and for the
other parent it was 17.5 mmol UDP-Glc/h/g hgb, which
is also within the reported carrier range, although clearly
there is overlap between the high end of this range and
the low end reported as normal (17.1–40.1mmol UDP-
Glc/h/g hgb) (Shin 1991). Consistent with data from
“low hGALE activity” control lines or “high hGALE
activity” patient lines, we observed no statistically sig-
niﬁcant metabolic abnormalities in these cells, after their
exposure to environmental galactose (data not shown).
Mutations Detected in Patients with Partial GALE
Impairment
Finally, as a step toward addressing the molecular ba-
sis of differential hGALE impairment in different pa-
tients, we sequenced the hGALE alleles of eight patients
(16 alleles) in our study. As described in the “Material
and Methods” section, the regions sequenced included
both coding and noncoding domains stretching from
430 bp upstream of the hGALE translation initiation
site to 491 bp downstream of the hGALE stop codon.
In parallel, we also sequenced the hGALE alleles from
three normal controls (six alleles). Our results, sum-
marized in table 4 and table 5, demonstrated two main
points.
First, by comparing our sequences with those in
the reference sequence (GenBank accession number
AF022382), we identiﬁed 49 positions (table 5) at which
all our sequences, both control and patient, differed from
the reference sequence. It is important to point out that,
while distinct from the reference sequence, these base
changes were nonetheless identical in all 22 hGALE
alleles sequenced for this study, including 6 control al-
leles and 16 patient alleles representing at least four
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Table 4
Base Changes Found in hGALE-Deﬁcient Patients
Patient and Base Change
Amino Acid
Substitution Intron Reference(s)
FKE34a:
C3192T (het, unk) P293L … This article; S. M. Huguenin and T. Cowan, personal communication
FKE35:
A2712G (het, pat) K257R … Alano et al. 1997; Maceratesi et al. 1998; Wasilenko et al. 2005
C1623T (het, mat) Y136Y … Present article
C1639T (het, mat) L142 L … Present article
FKE37b:
C1664T (hom) T150M … Present article
FKE50:
G1698T (het, unk) K161N … Present article
G253A (het, unk) … A Present article
C839A (het, unk) … C Present article
FKE51:
G3270A (het, unk) G319E … Alano et al. 1997; Maceratesi et al. 1998; Wasilenko et al. 2005
G3226A (het, unk) N304N … Present article
A142T (het, unk) … A Present article
C232T (het, unk) … A Present article
T250C (het, unk) … A Present article
Ins TA after 250 (het, unk) … A Present article
A252G (het, unk) … A Present article
G349T (het, unk) … A Present article
FKE52:
G1267A (het, unk) Q99Q … Present article
G1590A (het, unk) K125K … Present article
G1738A (het, unk) D175N … Present article
FKE56a:
A2712G (het, unk) K257R … Alano et al. 1997; Maceratesi et al. 1998; Wasilenko et al. 2005
FKE57:
C1213G (het, unk) S81R … Present article
G3270A (het, unk) G319E … Alano et al. 1997; Maceratesi et al. 1998; Wasilenko et al. 2005
G1017C (het, unk) … C Present article
C1018A (het, unk) … C Present article
A1020G (het, unk) … C Present article
NOTE.—As indicated, some coding region base changes resulted in missense mutations, whereas others resulted in silent mu-
tations. het p heterozygous mutation; hom p homozygous mutation; pat p paternal origin; mat p maternal origin; unk p
parental origin unknown.
a Second mutation not identiﬁed despite completed sequence.
b Consanguineous.
different racial groups (Hispanic, African American,
mixed race including white, and Asian). Although 48 of
these changes impacted noncoding sequence, one was a
missense substitution (T2298C, encoding V180A) that
we had also reported elsewhere (Quimby et al. 1997).
At least 13 other hGALE cDNA or partial cDNA se-
quences available in GenBank agreed with our sequence
at this position (accession numbers NM_000403,
NM_001008216, BC001273, CR616589, CR611350,
CR602422, CR596991, CR592671, BC050685,
L41668, CR592211, CR616462, and CR601378). A
second human genomic GALE sequence (GenBank ac-
cession number AL031295) also varied from the
AF022382 reference sequence at all 49 positions noted
here, although, in three positions, the discrepancies were
distinct from those we observed. There were also nine
locations, all noncoding, at which our sequence agreed
with AF022382 but not with AL031295. Considering
these data together, we conclude that most, if not all, of
the 49 base changes we identiﬁed in both patients and
controls represent either errors in the deposited sequence
or, alternatively, polymorphisms for which the sequence
reported here is by far the predominant allele. We have
deposited our normal hGALE genomic sequence and
also a corrected version of the coding sequence in
GenBank for future use as reference alleles (accession
numbers DQ233667 [gene] and DQ233668 [coding
sequence]).
The second conclusion resulting from our sequencing
data is that most nonconsanguineous patients are com-
pound heterozygotes who carry a mix of coding and
noncoding base substitutions. Whereas some of these
substitutions have been reported elsewhere (e.g., K257R
or G319E [Alano et al. 1997; Maceratesi et al. 1998;
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Table 5
Base Changes Relative to the hGALE Reference
Sequence Found in All Patient and Control Alleles
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Wasilenko et al. 2005] and P293L [S. M. Huguenin and
T. Cowan, personal communication]), the majority iden-
tiﬁed in this study (table 4) were novel. Future studies
will explore the functional signiﬁcance of these substi-
tution mutations.
Discussion
The data reported here demonstrate two fundamental
points with regard to epimerase-deﬁciency galactosemia.
First, biochemical hGALE deﬁciency is not a binary con-
dition; it is a continuum disorder. Not all the infants
ascertained for this study with RBC epimerase deﬁciency
exhibited normal hGALE activity in nonperipheral cells.
We propose to apply the term “intermediate GALE de-
ﬁciency” to patients who exhibit partial impairment of
hGALE activity in nonperipheral cells, such as lympho-
blasts. It is also important to note that many patient
lines demonstrated impairment of hGALE activity, not
only with regard to UDP-Gal but also with regard to
UDP-GalNAc. Considering the importance of both re-
actions to the maintenance of normal UDP-sugar pools
in mammalian cells, it remains unknown which loss of
activity plays the greater role in deﬁning patient outcome
in epimerase-deﬁciency galactosemia.More in-depth and
long-term studies of these and other patients may help
to address this question. Finally, it is important to stress
that, whereas all the patients ascertained exhibited RBC
hGALE impairment, there was no statistically signiﬁcant
correlation between the degree of RBC hGALE impair-
ment and the degree of lymphoblast hGALE deﬁciency
observed. This is an important point, because it under-
scores the reality that RBC hGALE activity level cannot
be used to distinguish peripheral from intermediate or
other forms of epimerase-deﬁciency galactosemia. This
point further raises the possibility of tissue-speciﬁc fac-
tors that inﬂuence either expression or function of
hGALE. This concept is fully consistent with previous
reports of tissue-speciﬁc GALE impairment in patients
with peripheral epimerase deﬁciency (Gitzelmann 1972;
Gitzelmann and Steimann 1973; Mitchell et al. 1975;
Gitzelmann et al. 1977). One likely factor that may con-
tribute to loss of GALE activity in RBCs relative to ﬁ-
broblasts or lymphoblasts is compromised stability. In-
deed, we have previously demonstrated evidence of
instability in the proteins encoded by a small number of
hGALE alleles derived from patients with ostensibly pe-
ripheral GALE deﬁciency (Wohlers et al. 1999). The pos-
sibility of other factors that contribute as tissue-speciﬁc
modiﬁers of hGALE expression or function remains an
open question.
Second, many of the intermediate hGALE deﬁciency
lymphoblast lines studied here and at least some of the
patients from whom these lines were derived demon-
strated metabolic evidence of impaired galactose metab-
olism both in vitro and in vivo, in the presence of en-
vironmental galactose, and, in some cases, also in the
absence of galactose. The most notable metabolic ab-
normalities observed in the presence of environmental
galactose included markedly elevated Gal-1P and UDP-
Gal and depressed UDP-Glc. The most notable meta-
bolic abnormalities observed in patient cells cultured in
the absence of environmental galactose included mildly
elevated UDP-Gal and depressed UDP-Glc. It is impor-
tant to point out that, whereas no free galactose was
intentionally added to the medium bathing these cells,
their medium did contain 10% fetal bovine serum,which
is rich in glycoproteins and glycolipids that could serve
as substrates for a salvage pathway (Krieger et al. 1989),
thereby providing a “backdoor” supply of low levels of
exogenous galactose to the cells. The ratio of UDP-Glc/
UDP-Gal detected in control lymphoblasts cultured in
both the presence and absence of galactose was between
0.5 and 0.67; this value is low compared with the 1.4
ratio reported elsewhere for human lymphoblasts
(Wehrli et al. 2001). The basis for this disparity remains
unknown but may reﬂect differences in the culture con-
ditions used or in the procedures used for cell harvest,
sample preparation, or analysis. What is striking is that
the UDP-Glc-to-UDP-Gal ratio in the more severely
hGALE-impaired patient cells was close to 0.1 in the
absence of galactose and close to 0.02 in the presence
of galactose. This is an extremely abnormal ratio and
could have signiﬁcant implications for the ability of these
cells to synthesize normal glycoproteins and glycolipids.
As mentioned above, one patient with low lympho-
blast hGALE activity was also monitored with regard
to RBC galactitol and galactonate, both while on dietary
restriction of galactose and then again after the intro-
duction of dietary galactose. This patient demonstrated
abnormally low levels of both metabolites in the absence
of dietary galactose, and both values essentially nor-
malized in response to treatment with dietary galactose.
This result is striking not only because it serves as further
evidence of abnormal galactose metabolism in vivo in a
patient with intermediate GALE deﬁciency but also be-
cause this result is the opposite of what is seen for pa-
tients with transferase-deﬁciency galactosemia. Patients
with even partial (Duarte/classic compound heterozy-
gous galactosemia) GALT deﬁciency often demonstrate
elevated, not depressed, levels of RBC galactitol and gal-
actonate relative to age-matched controls (Yager et al.
2003; Ficicioglu et al. 2005).
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At present, the clinical signiﬁcance of all these met-
abolic abnormalities remains unclear but, given that
some of the patients on normal diets (e.g., FKE37 and
FKE52) demonstrated Gal-1P levels indistinguishable
from those seen in treated patients with classic galac-
tosemia, the concern remains that at least some patients
with intermediate hGALE deﬁciency who are not treated
may be at risk for long-term complications. Given that
hGALE-deﬁciency in most patients is never diagnosed
or, if it is diagnosed, those patients are lost to follow-
up at an early age, the long-term outcome for most pa-
tients is never ascertained. Future large-scale, longitu-
dinal studies will be required to address this issue.
Unfortunately, states that drop total galactose (Gal 
Gal-1P) screening from their newborn proﬁles will fur-
ther exacerbate the current problem, since all patients
with epimerase-deﬁciency galactosemiawill demonstrate
normal GALT activity and will, therefore, slip through
an abbreviated screen undetected.
Impact of Impaired GALE in Mammalian Cells
Few studies have explored the biochemical or phe-
notypic impact of GALE impairment in mammalian cells
cultured in the presence or absence of exogenous galac-
tose (Robinson et al. 1963, 1966; Kingsley et al. 1986a,
1986b; Krieger et al. 1989; Schulz et al. 2005). Perhaps
the best studied of these cells are the Chinese hamster
ovary (CHO) cell–derived ldlD line, originally selected
on the basis of impaired LDL receptor function by Krie-
ger and colleagues (1981). Subsequent studies (Kingsley
et al. 1986a; Krieger et al. 1989) deﬁned this phenotype
as secondary to a complete loss of GALE activity, re-
sulting in the abnormal processing of both N- and O-
linked glycoproteins, including the LDL receptor. These
studies further demonstrated that, whereas supplemen-
tation of the culture medium with low levels of galactose
and GalNAc restored both glycoprotein processing and
LDL receptor function, supplementation of the medium
with 1125 mM galactose resulted in impaired ldlD cell
growth. Normal CHO cells exposed to galactose in par-
allel demonstrated no growth abnormalities (Krieger et
al. 1989).
Recent studies from our laboratory both conﬁrmed
and extended these earlier reports (Schulz et al. 2005).
In particular, we demonstrated that not only ldlD cells
alone, which exhibit no detectable GALE activity, but
also ldlD cells transfected to express low (5%–10% of
wild-type) levels of hGALE are growth impaired in the
presence of 250 mM galactose. We further demonstrated
that both ldlD cells and ldlD cells expressing low levels
of hGALE accumulate abnormally high levels of Gal-1P
and UDP-Gal and abnormally low levels of UDP-Glc
upon exposure to 250 mM galactose. Both wild-type
CHO and ldlD cells transfected to express wild-type lev-
els of hGALE did not display these abnormalities (Schulz
et al. 2005).
The quantitative relationship between the level of
GALE expression and both the requirement for and the
sensitivity to exogenous galactose in mammalian cells
remains unclear. The most severely hGALE-impaired pa-
tients reported to date (Walter et al. 1999) are all ho-
mozygous for the V94M mutation associated with at
least 5% residual activity (Wohlers et al. 1999; Wohlers
and Fridovich-Keil 2000). These cells fail to demonstrate
abnormal LDL receptor structure or function in culture
(Kingsley et al. 1986b), although these patients clearly
display a spectrum of metabolic and other abnormalities,
some likely related to hGALE dysfunction, others likely
not related (Walter et al. 1999). Finally, results reported
here demonstrate that patients and/or their cells with
intermediate levels of hGALE impairment can display
abnormally high levels of Gal-1P in the presence of ga-
lactose and abnormally high levels of UDP-Gal and low
levels of UDP-Glc even in the absence of galactose. These
data clearly support the conclusion originally put for-
ward by Kalckar (1965) that, unlike patients with classic
galactosemia, GALE-deﬁcient patients may require at
least a limited amount of dietary galactose for normal
homeostasis.
Our studies of ldlD cells demonstrated that uridine
supplementation resolved some but not all of the growth
and metabolic abnormalities in these GALE-deﬁcient
cells upon exposure to exogenous galactose (Schulz et
al. 2005). Studies are currently under way to test the
impact of uridine supplementation on patient cells.
Mutations in hGALE
From hGALE sequence analysis of eight of the patients
in this study, we identiﬁed 23 distinct base changes, of
which 20 were novel (table 4). All of the changes iden-
tiﬁed were found in the heterozygous or compound het-
erozygous state, except for a T150M missense substi-
tution, which was found in the homozygous state in one
patient of consanguineous origin. Of the six novel mis-
sense substitution mutations reported here, only one,
K161N, impacts a residue that is fully conserved among
the human, rat, yeast, and E. coli GALE sequences.
Nonetheless, most of the amino acid substitutions are
themselves nonconservative.
Surprisingly, most patients did not demonstrate pre-
cisely two mutations. Five patients (FKE35, FKE50,
FKE51, FKE52, and FKE57) each demonstrated three
or more base changes, the majority of which were either
noncoding or silent substitutions. Future studies will be
required to dissect the functional signiﬁcance of each of
these base changes and to deﬁne each as either a causal
mutation or a neutral polymorphism. Two additional
patients (FKE34 and FKE56) each demonstrated only a
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single heterozygous mutation, despite complete sequenc-
ing of the hGALE locus. The absence of a second de-
tectable mutation in each of these patients remains un-
explained, although either of two possibilitiesmay apply.
First, there may be a second mutation that was not de-
tected by our sequencing strategy. Extreme upstream or
downstream regulatory mutations outside the targeted
area, for example, would not have been detected. Al-
ternatively, a partial gene deletion may have precluded
PCR ampliﬁcation of portions of one GALE allele, al-
though the fact that one mutation was detected in the
heterozygous state in each of these patients rules out the
possibility of a full hGALE gene deletion. Future studies
will address this question. The second possible expla-
nation is that the two heterozygous “patients” are ac-
tually heterozygote carriers, and there is no second mu-
tation. Parental studies will be required to address this
possibility.
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Accession numbers and URLs for data presented herein are as
follows:
ExPASy, http://us.expasy.org/ (for GALK [EC 2.7.1.6], GALT [EC
2.7.7.12], and GALE [EC 5.1.3.2])
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for hGALE refer-
ence sequences [accession numbers AF022382, NM_000403,
NM_001008216, BC001273, CR616589, CR611350, CR602422,
CR596991, CR592671, BC050685, L41668, CR592211,
CR616462, CR601378, AL031295, DQ233667, and DQ233668])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/entrez/Omim/
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